How to Price a TRT Program

Price the year, not the visit

A TRT program is priced badly almost every time for the same reason: the owner prices the first appointment. The intake is where all the visible work happens, so it feels like the product, and the monthly fee gets set to whatever sounds reasonable next to the clinic across town. Then twelve months later the picture is strange. The patients are stable, the schedule is light, the drug barely costs anything, and the profit is still thin. The fee was never built on the shape of the actual year.

The shape is what you are really pricing. A hormone program is a heavy first month followed by a long run of very light ones, and the fee has to cover both without the light months quietly paying off the heavy one. If you have not already, the profitability of a hormone clinic covers why that structure makes TRT one of the better recurring cash-pay models. This post is narrower and more practical: exactly how to set the numbers so the recurring revenue turns into recurring profit.

The pricing models, and what each one is good at

Almost every TRT program is a version of one of these. They are not mutually exclusive, and most mature programs run a base membership with a procedure line bolted on. What matters is knowing what each piece is doing for you and where it leaks.

• Monthly membership. A fixed monthly fee that covers the prescription, the light follow-ups, and usually a defined lab cadence. This is the engine. It is the easiest for a patient to say yes to and the easiest for you to plan against, and it renews while consuming almost no provider time once the patient is stable.
• Quarterly or annual plan. The same program billed in a longer block, often at a small discount for paying up front. It lowers churn and smooths cash flow, but be careful: a quarterly fee that looks generous can bury an intake quarter that was far more expensive to serve than the three that follow.
• Bundled labs. Labs folded into the membership on a set schedule rather than billed each time. Simple for the patient and a clean retention hook, but only safe if you have priced the fee to clear its floor when every included panel is actually run, not when half of them get skipped.
• Pellet as a per-procedure add-on. For patients on that route, the insertion is billed as its own discrete fee a few times a year, separate from the base membership. It carries real provider time and a consumable cost per insertion, so it should be priced on its own terms, never absorbed into the monthly number.

The base membership is the recurring engine. The pellet line is a discrete procedure. The moment you blend a per-procedure cost into a flat monthly fee, you have stopped being able to see which one is actually earning.

What the fee covers, and what each part costs

Before you can put a number on the program, you have to decide exactly what the fee buys. Every line below is either something the membership covers (and therefore something you have to price in) or something the patient pays for separately. Getting this list explicit is half the job.

The four things a fee has to account for

• Visits. The initial consult and the periodic follow-ups. Nearly all of this is intake. A stable patient needs only a brief check-in each quarter, so the ongoing visit load is genuinely small.
• Labs. The baseline panel at intake and the monitoring panels through the year. Decide whether these are included in the fee, billed as a pass-through at your cost, or a modest margin line. There is no wrong answer, but there is a wrong outcome: giving them away without pricing them in.
• Medication. The single biggest decision in the whole model. Either the drug is included in the fee, or it is a pass-through the patient pays your pharmacy or your in-house dispense cost for. Included is cleaner for the patient; pass-through protects you if drug pricing moves. Whichever you pick, the marginal cost of most testosterone protocols is low, so this is rarely the number that decides the fee.
• Dose management and messaging. The line owners forget entirely. Titration questions, side-effect messages, refill requests, and portal replies are real provider or staff minutes, and they cluster in the first few months. This time is invisible on the schedule, which is exactly why it goes unpriced.

One caution worth stating plainly, and it is the same one that runs through the profitability overview: what you may source, compound, dispense, or mark up varies widely by state, by your medical-director arrangement, and by whether you use a compounding pharmacy or dispense in-house. Treat every drug and lab figure here as illustrative of the shape, not a quote, and settle the legal and supervision questions before the financial ones.

The cost stack is small and front-loaded

Here is what makes TRT pricing forgiving once you understand it. The cost to serve a patient is both low and unevenly distributed across the year. Break it into its parts and the picture is clear.

• Drug: low. A course of injectable testosterone runs at a marginal cost that is small relative to what a program charges. This is a cost observation, not a medical or pricing claim. Compounded and topical preparations tend to sit in a similar place. The drug is almost never the constraint.
• Labs: modest, and heaviest at intake. The baseline panel is the biggest single lab expense; the monitoring panels through the year are lighter. If you send patients to a reference lab or a third party, this may carry little margin and simply be a necessary, recurring reason to stay engaged.
• Provider time: front-loaded and then very light. This is the real cost, and it lands almost entirely up front. A new patient can consume well over an hour across the consult, lab review, protocol design, and the flurry of early titration messages. Six months later the same patient might need fifteen minutes a quarter.

That last line is the whole game. Because the expensive resource is provider time, and because provider time is spent almost entirely at the start, the number that decides your profit is not the drug and not the labs. It is how much each provider-hour earns, and how honestly you accounted for the hours the first few months actually consume.

Setting the fee from a target profit per provider-hour

The method is the same disciplined build you would use for any service, with one adjustment: you are pricing a year of light touches plus a cheap drug, priced off a heavy intake, not a single appointment. Work it in this order and price the intake as its own line so the front-loaded time is paid for when it happens.

1. Total the annual cost to serve a stable patient: the drug for the year, the monitoring labs you include, and the consumables. For most protocols this total is modest.
2. Count the maintenance provider-hours realistically, using your own cadence. A stable patient on a quarterly check-in consumes roughly an hour across the whole year once intake is behind them, plus a little for messaging.
3. Add the overhead share for those provider-hours, exactly as you would for any service. That is the floor the membership must clear.
4. Add your target profit per provider-hour on the maintenance time. Divide the annual total by twelve, and you have the lowest monthly fee that hits your target once a patient is stable.
5. Price the intake separately as its own charge, sized to the heavy first-month hours plus the baseline panel. This is the step that keeps the recurring math honest.

If you have never put a dollar figure on a provider-hour before, the mechanics of calculating profit per provider-hour are worth a read first, because that single number is the anchor the whole fee hangs from.

A worked example: intake month vs maintenance month

Take one patient on a $189 monthly membership with a $300 one-time intake charge, quarterly monitoring labs, and testosterone included in the fee (illustrative figures, in a conservative range, not a specific clinic). Use an overhead share of $80 per provider-hour throughout. The two months that matter look nothing alike.

A steady-state maintenance month

• Fee collected: $189.
• Drug cost: about $15 for the month.
• Labs this month: $0 (labs run quarterly, not this month).
• Provider time: roughly 0.25 hours, one short check-in.
• Overhead share: 0.25 hours at $80, so $20.

Run it. The patient pays $189. Against that you spend $15 in drug and $20 in overhead, for $35 of cost. Contribution is $189 minus $35, or $154, on 0.25 provider-hours. That is roughly $616 of profit per provider-hour ($154 divided by 0.25), the exceptional figure that exists only because the drug is cheap and the maintenance time is almost nothing.

Maintenance month profit per provider-hour = (fee minus drug minus labs minus overhead share) divided by provider-hours. Here: ($189 minus $15 minus $0 minus $20) divided by 0.25 = $154 divided by 0.25 = about $616 per hour.

The intake month

• Membership fee: $189.
• Intake charge: $300, billed separately.
• Drug cost: about $15.
• Baseline lab panel: about $250.
• Provider time: roughly 1.25 hours across consult, lab review, protocol, and early titration messages.
• Overhead share: 1.25 hours at $80, so $100.

Priced correctly, the patient pays $189 plus the $300 intake, or $489. Against that you spend $15 in drug, $250 in labs, and $100 in overhead, for $365 of cost. Contribution is $489 minus $365, or $124, on 1.25 provider-hours, which is roughly $99 per provider-hour($124 divided by 1.25). That is a thin month, and it should be. The intake month is where you earn the right to the recurring revenue, not where the recurring profit lives.

Now watch what happens if you skip the intake charge and fold that first month into the membership like a lot of clinics do. The revenue is $189, the cost is still $365, and the month runs at a loss of about $176. You did not lose money treating the patient. You lost money by pricing the heaviest month as if it were a light one. Spread that loss across the year and it quietly eats the maintenance profit you were counting on.

Same patient, same drug, same labs. Bill the intake as its own line and the month clears $99 an hour. Bury it in a flat membership fee and the month runs a $176 loss. The only thing that changed was whether the heavy month was allowed to pay for itself.

Zoom out to the full first year and the model works because eleven light months carry one heavy one. Twelve months of membership at $189 is $2,268, plus the $300 intake is $2,568 collected. Across the year the drug runs about $180, the labs (a $250 baseline plus three $150 monitoring panels) run $700, and the provider time totals about 2 hours (1.25 at intake plus roughly 0.75 across the maintenance touches), so overhead at $80 an hour is $160. Total cost is $1,040. Annual contribution is $2,568 minus $1,040, or $1,528, on about 2 provider-hours, which is roughly $764 per provider-hour for the year. That is the number the fee was built to produce, and it only holds because the intake was paid for on its own.

Breakage, utilization, and the mistakes that undo the math

Two forces move the real number away from the model. Utilization is how much of the included benefit patients actually consume: a generous lab cadence only stays affordable if you price it at full use, not at the rate people actually show up. Breakage is the opposite, the members who pay and do not fully use what they bought, the skipped check-ins and unrun panels. Some breakage is real and healthy. The trap is pricing a program so it only works when breakage is high, which is a bet that your best patients will keep paying for something they never use.

The mistakes that undo TRT pricing are consistent, and every one of them is a version of pricing the light year and forgetting the heavy month:

• Underpricing the intake labor. The single most common error. The first month can carry an hour or more of provider time plus the baseline panel, and folding it into a flat fee means the maintenance months silently subsidize it, exactly as the worked example showed.
• Giving the labs away. Bundling a generous panel cadence into the fee without checking that the fee still clears its floor when every included panel is actually run. Decide deliberately whether labs are a margin line, a pass-through, or a retention tool, and price to match.
• Ignoring the maintenance load. Assuming a stable patient is free. The check-ins are light but not zero, and the messaging time between visits is real. Count it, or your profit per provider-hour is fiction.
• Blending the pellet into the membership. A per-procedure line with its own time and consumable cost does not belong inside a flat fee. Price it separately or you lose the ability to see whether the procedure side is earning at all.

Every mistake here has the same root: a fee built on the light maintenance year with the heavy intake month hidden inside it. Separate the two and price each honestly, and the program does what it is supposed to do.

See it on a full sample practice

A TRT program is one of the strongest recurring-revenue models in cash-pay medicine, but only if the fee is built on the real shape of the year: a heavy intake paid for on its own, and a long run of light, high-margin maintenance months. Revenue per patient tells you almost nothing here, because the same fee can represent a loss-making first month or a nearly free one. The number that tells the truth is the contribution of a patient against the provider-hours they actually consume, ranked beside every other line in the practice. The Inside Look walks a complete sample practice through exactly that view: every service and program ranked by profit per provider-hour, with a forecaster that shows how repricing a program or moving maintenance to a delegated provider ripples to the bottom line, no new patients required.

If you are building or repricing a program, start from profit per provider-hour as the anchor, then read the hormone clinic profitability overview for the wider economics the fee sits inside. Price the intake as its own line, price the maintenance like the high-margin, low-time asset it really is, and the years of renewals compound in your favor instead of against it.